ClinicalTrials.gg
Not yet recruitingNCT07814339Updated Sep 10, 2026

Hydrochloroquinine & Decitabine With Venetoclax in AML

A Phase 1 interventional study of Hydroxychloroquine and Venetoclax in Acute Myeloid Leukemia, sponsored by Rutgers, The State University of New Jersey. Not yet recruiting. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Rutgers, The State University of New Jersey · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Planned enrollment
176th of 202
18 · median 57
Started
2026
with 27 others
Phase 1
38 of 202
16 open now
Primary completion
2028-06
later than 100 of 143 live
Registered
194th of 202
by date

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 176th largest by planned enrollment, is one of 28 that started in 2026, is one of 38 in phase 1, reaches primary completion later than 100 of the 143 other live ones, and was the 194th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Phase I:

Primary Objective:

- Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of the o-Dec, ven, and HCQ

Secondary Objectives:

  • Characterize the safety profile of the triplet
  • Estimate the efficacy of the combination to induce remission
Read the detailed description

Relapsed / refractory (R/R) AML remains a therapeutic dead end, with real-world series reporting a median overall survival of under six months, even with intensive salvage approaches. Although the hypomethylating-agent/BCL-2 inhibitor doublet of decitabine (now available as the oral cedazuridine-boosted formulation) plus venetoclax yields encouraging remission rates, most responders ultimately relapse, underscoring an urgent need for resistance-modifying strategies. Converging pre-clinical and translational data show that AML blasts upregulate cytoprotective autophagy to evade BCL-2-mediated apoptosis; pharmacologic blockade of autophagosome-lysosome fusion with chloroquine analogues reverses this escape and synergizes with both venetoclax and cytotoxic backbones. Hydroxychloroquine, the only orally available autophagy inhibitor with a long safety record, therefore represents a pragmatic, mechanism-based addition to an all-oral decitabine / venetoclax regimen. The proposed Phase I study is significant because it will be the first to co-target aberrant DNA methylation, intrinsic apoptosis, and adaptive autophagy in R/R AML, aiming to convert transient responses into durable remissions while preserving outpatient convenience. Success would not only fill a critical therapeutic gap for patients who otherwise face dismal prognoses but also provide clinical proof-of-concept that autophagy inhibition can extend the utility of venetoclax-based regimens across hematologic malignancies.

Venetoclax (VEN), a selective BCL-2 inhibitor, in combination with a hypomethylating agent (HMA) or low-dose cytarabine, has re-defined first-line therapy for older or unfit adults with acute myeloid leukemia (AML).In VIALE-A, azacitidine + VEN yielded an approximately 65% composite complete remission (CR + CRi) rate and a median overall survival (mOS) of 14.7 months versus 8 months with azacitidine alone. Despite these gains, the majority of responders ultimately progress; up to 42% relapse by two years in long-term follow-up of VIALE-A, and real-world datasets mirror these findings.[ Outcomes after VEN failure are dismal. A 2025 multicenter Spanish series reported an mOS of only 2.3 months following relapse or primary refractoriness to VEN-HMA, with a salvage treatment rate of 30% and an overall response rate (ORR) of 23% among those treated. Smaller US single-institution cohorts and ASH abstracts have described similar post-VEN mOS figures of 6 months and highlight the absence of a standard salvage approach.Thus, venetoclax-resistant relapsed/refractory (R/R) AML represents a high-mortality population with an urgent unmet need.

AML stem and progenitor cells are often in a state referred to as "primed" for mitochondrial, or intrinsic, apoptosis-meaning they are close to the threshold of undergoing programmed cell death. This apoptotic readiness is governed by the balance between pro-apoptotic and anti-apoptotic members of the BCL-2 protein family within the mitochondria. In many AML subtypes, particularly in leukemic stem-like cells, survival is heavily dependent on the anti-apoptotic protein BCL-2, which functions by binding to and sequestering key pro-apoptotic effectors such as BIM and BAX. BIM is a BH3-only activator protein, and BAX is a pore-forming effector that oligomerizes to disrupt the mitochondrial outer membrane, a critical step in the initiation of apoptosis.

VEN, a selective BCL-2 inhibitor, disrupts this protective interaction by displacing BIM from BCL-2. Once liberated, BIM is able to activate BAX and/or BAK, leading to mitochondrial outer membrane permeabilization (MOMP). This event triggers the release of cytochrome c into the cytosol, which binds APAF1 and forms the apoptosome, culminating in the activation of caspase-9 and downstream executioner caspases such as caspase-3 and caspase-7, the hallmark steps of intrinsic apoptosis. The result is rapid and irreversible cell death in BCL-2-dependent AML blasts.

Clinical and translational studies have shown that venetoclax sensitivity varies by AML genetic subtype. The highest response rates are observed in AML with NPM1 or IDH1/2 mutations, which often exhibit strong BCL-2 dependence and low expression of alternative anti-apoptotic proteins, such as MCL-1. Similarly, secondary AML with spliceosome mutations (e.g., SRSF2, U2AF1, or SF3B1) demonstrates heightened apoptotic priming and increased venetoclax responsiveness. Conversely, monocytic AML subtypes tend to upregulate MCL-1 and BCL2A1, reducing reliance on BCL-2 and conferring intrinsic resistance to venetoclax. Thus, understanding the apoptotic dependencies of AML subtypes has become critical in tailoring venetoclax-based therapies.

Acquired resistance to venetoclax in AML is driven by a multifactorial interplay of genetic, metabolic, and epigenetic mechanisms. One prominent mechanism involves clonal evolution and signal transduction pathway reprogramming. Longitudinal genomic analyses of patients at the time of relapse following initial response to venetoclax frequently reveal the emergence of mutations in key oncogenic drivers such as FLT3-ITD, NRAS, KRAS, and PTPN11. These mutations are not typically present at diagnosis but arise under the selective pressure of therapy. They lead to reactivation of downstream signaling pathways, most notably the MAPK cascade, which in turn upregulates anti-apoptotic proteins like MCL-1 and BCL-xL, thereby bypassing the BCL-2 dependence that venetoclax targets.

In addition to genetic adaptations, resistant AML blasts undergo profound metabolic rewiring, particularly within the mitochondria. These cells enhance their electron transport chain (ETC) capacity, replenish tricarboxylic acid (TCA) cycle intermediates, and activate antioxidant defense programs. This metabolic plasticity helps leukemic cells maintain mitochondrial integrity and survive even in the presence of BCL-2 inhibition, effectively diminishing venetoclax efficacy.

Finally, epigenetic reprogramming plays a significant role in acquired resistance. AML cells can dynamically remodel chromatin architecture - such as through changes in histone modifications like H3K27 acetylation - leading to a rebalanced expression of BCL-2 family proteins. These epigenetic changes shift the apoptotic threshold and may confer a resistance phenotype that can be reversible. Notably, agents targeting chromatin regulators, such as BETs (bromodomain and extraterminal domain) or LSD1 (lysine-specific demethylase 1) inhibitors, have demonstrated potential in restoring venetoclax sensitivity by reversing these epigenetic adaptations.

In response to the growing challenge of venetoclax (VEN) resistance in acute myeloid leukemia (AML), several innovative therapeutic strategies are being explored, both in preclinical models and early-phase clinical trials. One potentially promising approach involves directly targeting MCL-1, a key anti-apoptotic protein frequently upregulated in VEN-resistant AML. Selective MCL-1 inhibitors, such as S64315 (also known as MIK665), have demonstrated potent synergistic activity with venetoclax in preclinical studies, effectively eradicating resistant AML xenografts. Clinical evaluation is ongoing, with early-phase trials testing agents like AZD5991 (NCT03218683) and S64315 with or without venetoclax (NCT03672695). However, cardiac toxicity, particularly QT prolongation and ventricular dysfunction, remains a major safety consideration in this class.

Another promising avenue targets the Menin-KMT2A (formerly MLL) and NPM1 transcriptional axis, which contributes to leukemogenesis and BCL-2 family dysregulation.[ Small-molecule menin inhibitors such as revumenib and ziftomenib have shown the ability to restore myeloid differentiation and downregulate MCL-1 expression. Early clinical data in relapsed/refractory (R/R) AML patients previously exposed to venetoclax demonstrate complete remission or complete remission with partial hematologic recovery (CR/CRh) rates ranging from 20% to 40%, with encouraging durability of response when combined with venetoclax. However, these agents would only serve the approximately 35% of AML patients with NPM or KMT2A alterations.

To further enhance efficacy and prevent resistance escape, triplet regimens that concurrently inhibit compensatory signaling pathways are gaining traction. In patients with FLT3-mutated AML, the combination of a FLT3 inhibitor (e.g., gilteritinib or quizartinib) with a hypomethylating agent (HMA) and venetoclax has shown composite response rates exceeding 70%, including substantial activity in those with prior venetoclax exposure. These regimens are advancing to randomized phase III trials. Likewise, for RAS-mutated AML, preclinical studies suggest that dual targeting of MAPK signaling with trametinib and venetoclax induces synergistic cytotoxicity. This combination is currently being evaluated in phase I trials.

Modulation of the apoptotic pathway itself also represents a strategic target. SMAC mimetics (e.g., LCL161, ASTX660), which promote degradation of inhibitor of apoptosis proteins (IAPs), are under clinical investigation for their potential to re-sensitize venetoclax-resistant clones.Several of these agents are in phase Ib/II trials, independent of current frontline treatment protocols.

Finally, targeting the metabolic dependencies of AML cells is an emerging strategy aimed at reinforcing venetoclax cytotoxicity. Agents such as telaglenastat, a glutaminase inhibitor, and IACS-010759, a complex I inhibitor that blocks fatty acid oxidation, have shown preclinical efficacy in venetoclax-resistant AML by disrupting energy production and mitochondrial fitness and are in clinical testing.

Existing data show that post-VEN relapse/refractory AML carries an mOS of roughly 2-3 months, no approved therapies specifically address VEN-refractoriness. Despite the initial clinical efficacy of venetoclax and as discussed above, acquired resistance in acute myeloid leukemia (AML) remains a major barrier to durable remissions.[ Glytsou et al. have demonstrated that mitochondrial structural integrity and mitophagy are key elements of this resistance. Using a genome-wide CRISPR/Cas9 screens in human AML models identify mitochondrial organizing genes such as the mitochondrial chaperonin CLPB whose suppression sensitises AML cells to venetoclax.[44] They found that CLPB is upregulated in AML and further induced upon acquisition of Venetoclax resistance; mechanistically CLPB maintains mitochondrial cristae via interaction with the cristae-shaping protein OPA1. Loss of CLPB led to cristae remodeling, mitochondrial stress responses, and apoptosis, and synergised with ven and ven + aza. This work demonstrates mitochondrial architecture as a drug-gable vulnerability in venetoclax-resistant AML. Using multiple CRISPR/Cas9 loss-of-function screens and AML patient-derived xenograft models, they have also shown that overexpression of the mitochondrial fusion protein MFN2, enhanced mitochondria-ER contacts, and elevated mitophagy flux together allowed AML blasts to clear damaged mitochondria, thereby avoiding the mitochondrial outer membrane permeabilization (MOMP) triggered by BCL-2 inhibition. Inhibition (genetic or pharmacologic) of MFN2 or mitophagy regulators restored apoptotic sensitivity to BH3 mimetics, reducing leukemia burden in vivo. These data provide a mechanistic foundation for combining ven with mitophagy/mitochondrial-dynamics inhibitors as a rational salvage strategy.

Hydroxychloroquine is a lysosomotropic agent that accumulates in lysosomes, raises intralysosomal pH, and inhibits the fusion of autophagosomes (and mitophagosomes) with lysosomes.[In this way, HCQ effectively blocks the late stage of autophagy/mitophagy. In the AML context, this means that when mitochondrial damage is induced (for example by BCL-2 inhibition via venetoclax leading to mitochondrial outer membrane stress), the resistant AML cell cannot clear damaged mitochondria efficiently via mitophagy. The accumulation of damaged mitochondria leads to increased ROS, loss of mitochondrial membrane potential, disrupted cristae structure, and greater apoptotic priming. Thus, combining HCQ with venetoclax tilts the balance back toward mitochondrial apoptosis by disabling a resistance mechanism of enhanced mitophagy.

Therefore, we propose a study that will test hydroxychloroquine (HCQ) in combination with azacitidine in adults with venetoclax-resistant R/R AML. By selecting patients immediately at loss of VEN response, incorporating dynamic molecular profiling to confirm on-target pathway inhibition, and using composite CR with MRD negativity as the primary end-point, this trial seeks to define a new salvage backbone. Correlative assays will interrogate serial BCL-2 family protein dependencies, mitochondrial metabolism, and clonal evolution, directly addressing the biologic underpinnings outlined above. Given the bleak post-VEN prognosis and the mechanistic rationale for dual targeting, the study meets a pressing clinical need and is anticipated to inform future combinatorial strategies aimed at eradicating minimal residual disease and preventing early relapse in this high-risk population.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Confirmed acute myeloid leukemia per 2022 WHO (≥20 % blasts or genetically-defined AML) 2. Age ≥ 18 years on the date of consent Disease status 3. Phase I: (R/R) or newly-diagnosed, overy high risk defined as p53 mutation or secondary AML after MPN or chemotherapy/radiation exposure 4. An performance status of 0-2 5. Acceptable Organ function within 14 days of cycle 1 day 1 6. /ALT ≤ 3× ; total ≤ 1.5× ULN (unless Gilbert's) 7. > 60 mL/min (Cockcroft-Gault) 8. Subjects must have a baseline of less than 450 milliseconds (\<450 ms) White blood cells \< 25 × 10⁹/L before first dose of hypomethylating agent - debulking with hydroxyurea/leukapheresis or up to 6 doses of cytarabine 100mg-200mg if needed is acceptable.

9. , , and patients are eligible if viral load is undetectable on stable therapy Wash-out from prior therapies should be ≥14 days from the last cytotoxic or targeted agent, and recovery to ≤Grade 1 non-hematologic toxicity 10. Reproductive precautions 11.Negative serum β-hCG for ; agreement to use highly effective during treatment and ≥ 90 days after last dose Signed written and willingness to comply with study procedures

Exclusion criteria

  • Exclusion Criteria

    1. Leukemia subtype - Acute promyelocytic leukemia (APL, PML-RARA)
    2. CNS leukemia not cleared (\<5 WBC/µL \& no blasts), or symptomatic CNS involvement
    3. Recent or uncontrolled transplant-related complications HSCT ≤ 90 days before Day 1 Active grade ≥ 2 or systemic >10 mg/day prednisone-equivalent
    4. Concurrent requiring active therapy. Any adequately treated in-situ cancers or those not expected to interfere with endpoints are allowed.
    5. Active, uncontrolled infection (bacterial, viral, or fungal) despite appropriate antimicrobial therapy
    6. Cardiac risk, class III/IV heart failure, unstable angina, recent MI (\< 6 months), arrhythmia, Concomitant use of -prolonging medications that cannot be discontinued, or history of torsades de pointes
    7. Pregnant or breastfeeding.
    8. Patients with known G6PD deficiency.
    9. drug or major surgery within 28 days.
    10. Bleeding diathesis/coagulopathy that would preclude required marrow aspirates or lumbar puncture.
    11. Psychiatric or social condition that, in the investigator's judgment, would impair compliance with protocol-mandated visits/procedures.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Hydroxychloroquine + Oral Decitabine/cedurazidine+ Venetoclax Combination Therapy

    Participants in this arm will receive a combination of Hydroxychloroquine (HCQ), oral Decitabine/cedurazidine, and Venetoclax, The therapy is administered in cycles according to the protocol.

    Drug: Hydroxychloroquine · Drug: Venetoclax · Drug: Oral Decitabine/cedazuridine

Interventions

  • Hydroxychloroquine will be administered orally as part of a combination regimen with Decitabine (oral decitabine-cedazuridine) and Venetoclax. In the Phase I portion, hydroxychloroquine will be given at escalating dose levels using a BOIN design to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D).

  • Venetoclax is a potent, selective, orally bioavailable small-molecule inhibitor of the anti-apoptotic protein B-cell lymphoma-2 (BCL-2). It promotes apoptosis of malignant cells that are dependent on BCL-2 for survival. Venetoclax will be supplied through the study participants' commercial pharmacy. Venetoclax is supplied as film-coated oral tablets containing 10 mg, 50 mg, or 100 mg of active drug. Tablets are intended for oral administration only. No reconstitution or dilution is required

  • DrugOral Decitabine/cedazuridine

    Drug pages: Decitabine · Cedazuridine

    Oral decitabine/cedazuridine is a fixed-dose combination of decitabine, a hypomethylating agent (DNA methyltransferase inhibitor), and cedazuridine, a cytidine deaminase inhibitor that increases oral bioavailability of decitabine by preventing its rapid degradation in the gut and liver. Each tablet contains 35 mg decitabine and 100 mg cedazuridine. The combination provides systemic exposure comparable to that of IV decitabine 20 mg/m² given over 5 days. Oral decitabine/cedazuridine will be obtained through the study participant's commercial pharmacy.

06

What researchers measure

Primary outcomes

  1. Phase I - Primary Endpoint

    Incidence of dose-limiting toxicities (DLTs) during Cycle 1, nonhematologic toxicity, or prolonged cytopenia not attributable to AML

    Time frame: 8 to 12 months

Secondary outcomes

  1. Phase I - Secondary endpoints

    Overall response rate (ORR) = CR + CRi + CRh Event-free survival (EFS) from the start of therapy to failure (no CR by week 12), relapse, or death.

    Time frame: 8 to 12 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2028, 21 months later.

Of 308 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 89. This study's planned 21 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Sep 10, 2026
StartEst.
Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07814339
Responsible party
Neil Palmisiano, MD,MS (Co-Medical Director of the Office of Human Research Services, Rutgers Cancer Institute, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Sep 10, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Neil Palmisiano, MD
Contact
wesoloel@cinj.rutgers.edu
732-235-2465
Elayne Wesolowsky
Contact
wesoloel@cinj.rutgers.edu
Neil Palmisiano, MD
principal investigator · Rutgers University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydroxychloroquine · Venetoclax · Decitabine · Cedazuridine

Start the discussion